Neuren Pharmaceuticals
- Home
- Neuren Pharmaceuticals
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
About one in 9,000 females in Australia are diagnosed with Rett Syndrome at birth. In the US, about 15,000 girls and women suffer from it, and globally, this number grows to 350,000 females. The significance of its prevalence is nothing compared to its impact. The disorder can have a detrimental effect on the lives of
Read MorePublic
Pharmaxis welcomes leading medical researcher and healthcare investment guru as Director
As a medical research company, successful trial outcomes are a must but business acumen in understanding the market is no less important either. For clinical stage biotech company Pharmaxis (ASX: PXS), their latest addition to the Board of Directors line-up will offer them the best of both worlds with the appointment of healthcare investment researcher
Read MorePublic
Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
The complexity of the human body never ceases to amaze me. So many systems need to work together to carry out seemingly simple tasks like walking, breathing and digesting. This complexity means that from time to time the convoluted web of neurons, strands of DNA and woven matrices of bone can be subject to defects.
Read MorePublic
Neuren secures European patent for drug aimed to treat incurable brain disorders
Australian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable. The granting of the new patent is the third jurisdiction to do so for Neuren with the same application
Read MorePublic
